Physician profile

Carol C Skipper

Family Medicine · Jersey City, NJ

NPI 1821081415

$2,176.90

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$613.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,479.08 2019-2024 Breztri, Farxiga
Abbvie INC. $295.75 2021-2022
Allergan, INC. $194.14 2019-2020
Glaxosmithkline, LLC. $83.72 2019-2020
Lilly USA, LLC $43.75 2019
Novo Nordisk INC $27.46 2019
Horizon Therapeutics Plc $14.65 2021
Genentech USA, INC. $13.64 2019
Sanofi-Aventis U.S. LLC $13.46 2019
Teva Pharmaceuticals USA, INC. $11.25 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carol C Skipper

$2,176.90

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/785284/carol-c-skipper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.